NCT03155100 - Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 7, 2017

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions

Multiple Myeloma in Relapse

Interventions

DRUG

Carfilzomib for Inj 60 milligram (MG)

All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone

DRUG

Elotuzumab 400 MG

All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone

DRUG

Dexamethasone

All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone

Trial Locations (8)

Helsinki University Central Hospital, Helsinki

Central Finland Central Hospital, Jyväskylä

Kymenlaakso Central Hospital, Kotka

Kuopio University Hospital, Kuopio

Oulu University Hospital, Oulu

Tampere University Hospital, Tampere

Turku University Hospital, Turku

Karolinska University Hospital, Stockholm